Results 81 to 90 of about 92,350 (272)

Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study

open access: yesRheumatology and Therapy, 2018
Introduction This study was conducted to observe patterns of use of the interleukin-6 receptor-alpha inhibitor tocilizumab in routine clinical practice in patients with rheumatoid arthritis (RA).
Boulos Haraoui   +5 more
doaj   +1 more source

Prevalence of Dietary Supplement Use and Potential Medication Interactions Among Adults With Systemic Lupus Erythematosus

open access: yesArthritis Care &Research, EarlyView.
Objective The aim of this study was to characterize the prevalence and correlates of dietary supplement use, identify commonly used supplements, and evaluate potential supplement–medication interactions among adults with systemic lupus erythematosus (SLE).
Sarah L. Patterson   +7 more
wiley   +1 more source

Tocilizumab as a targeted immunomodulatory therapy in the management of severe respiratory illnesses: a multicenter cohort study of COVID-19 patients

open access: yesScientific Reports
Respiratory pandemics like COVID-19 continued to strain healthcare systems worldwide. Numerous antiviral, antimalarial, and anti-inflammatory treatments were administered to many patients to pursue effective therapeutics.
Abbas Al Mutair   +11 more
doaj   +1 more source

Real‐World Effectiveness and Safety of Secukinumab in Giant Cell Arteritis: An Italian Multicenter Cohort Study

open access: yesArthritis Care &Research, EarlyView.
Objective The objective of this study was to evaluate the real‐world effectiveness and safety of secukinumab in patients with giant cell arteritis (GCA). Methods This multicenter retrospective study included patients with GCA who received secukinumab at 14 Italian centers with at least six months of follow‐up.
Luca Iorio   +28 more
wiley   +1 more source

Patients Improve, Patterns Persist: Longitudinal Stability of Rheumatoid Arthritis Joint Involvement Patterns

open access: yesArthritis Care &Research, EarlyView.
Objective Rheumatoid arthritis is a heterogeneous disease. Data‐driven approaches, from synovial histology to joint involvement patterns (JIPs), have sought to define clinically meaningful subgroups. Whether these subgroups represent stable phenotypes or transient disease states remains unclear.
Tjardo Maarseveen   +24 more
wiley   +1 more source

Development of Patient‐Reported Outcome Measures for Early Systemic Sclerosis Across Disease Subtypes

open access: yesArthritis Care &Research, Accepted Article.
Objective Existing patient‐reported outcome (PRO) measures for systemic sclerosis (SSc) have important limitations, including inadequate coverage of early disease and limited inclusion of diffuse cutaneous (dcSSc) and limited cutaneous (lcSSc) subtypes.
George J. Greene   +5 more
wiley   +1 more source

Oral glucocorticoids added to ILD‐modifying therapy in systemic sclerosis‐associated interstitial lung disease: a target trial emulation study from the EUSTAR database.

open access: yesArthritis Care &Research, Accepted Article.
Objectives We aimed to estimate whether adding oral glucocorticoids to ILD‐modifying therapy improves 12‐month lung outcomes in systemic sclerosis‐associated interstitial lung disease (SSc‐ILD). Methods We emulated a target trial using the EUSTAR database.
Zubeyir Salis   +14 more
wiley   +1 more source

Acute appendicitis in a rheumatoid arthritis patient treated with tocilizumab: report of a case

open access: yes, 2015
A 55-year-old woman had been treated for rheumatoid arthritis with tocilizumab 1 month prior to the onset of mild abdominal pain. Computed tomography revealed swelling of the appendix and ascites around the appendix.
Koga, Naoki   +6 more
core  

The Clinical Value of Inflammatory Indicators at the Time of Secondary Infection After Treatment With Tocilizumab: A Cross‐Sectional Study

open access: yesHealth Science Reports
Background and Aims Tocilizumab, an anti‐inflammatory agent used in severe COVID‐19 infection, is known to inhibit the Interleukin 6 receptor and reduce C‐reactive protein (CRP) resulting in an increased risk of secondary infections.
Dena Firouzabadi   +4 more
doaj   +1 more source

Intelligent Programmable Membrane Nanosponge for Early Virus Blocking

open access: yesAdvanced Science, EarlyView.
A smart programmable nanosponge (ACNPs) displays high‐density viral receptors on its membrane and encapsulates fusion inhibitors to capture virions at the infection source through competitive binding and blocks their entry through protease inhibition for ultra‐early cascade interception. This modular, mucus‐penetrating platform shifts antiviral defence
Ze Chen   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy